Prognose

Kaufen	2
Halten	0
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	3 / 18
Levermann-Strategie	-3 / 13

Beliebteste Broker

News

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102. “We are appreciative of the support from new and existing investors including OrbiMed, Janus Henderson Investors, Tybourne Capital Management, Alger, Ikarian Capital, LLC, BVF Partners LP, and Th.» Mehr auf businesswire.com
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).» Mehr auf zacks.com
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards to purchase a total of 70,000 shares of common stock to new non-exec.» Mehr auf businesswire.com

Unternehmenszahlen

Im letzten Quartal hatte FORTE BIOSCIENCES INC einen Umsatz von 0,00€ und ein Nettoeinkommen von −7,54 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	100,00%
Nettoeinkommen	−7,54 Mio	19,86%
EBITDA	−7,74 Mio	19,77%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+22,45 Mio€
Anzahl Aktien	1,46 Mio
52 Wochen-Hoch/Tief	+20,40€ - +3,94€
Dividenden	Nein
Beta	1,46
KGV (PE Ratio)	−0,86
KGWV (PEG Ratio)	−0,03
KBV (PB Ratio)	+3,16
KUV (PS Ratio)	+3.898,48

Unternehmensprofil

Forte Biosciences, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium in den Vereinigten Staaten. Es entwickelt das Programm FB-102, das verschiedene Autoimmunkrankheiten wie Vitiligo und Alopecia areata behandelt. Der Hauptsitz des Unternehmens befindet sich in Dallas, Texas.